GDRX (GoodRx Holdings) ROE %: 0.76% (As of Mar. 2026)


GDRX GoodRx Holdings Inc GDRX
60 GF Score
Price $2.70
GF Value $5.66
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is GoodRx Holdings ROE %?

GoodRx Holdings GDRX -2.18% 60 ROE % is 0.76% as of Mar. 2026. GuruFocus rates GDRX with a GF Score™ of 60/100 and a GF Value™ of $5.66 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 628 Healthcare Providers & Services companies, GoodRx Holdings ranks worse than 57.8% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. GoodRx Holdings's annualized net income for the quarter that ended in Mar. 2026 was $4.7 Mil. GoodRx Holdings's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $619.1 Mil. Therefore, GoodRx Holdings's annualized ROE % for the quarter that ended in Mar. 2026 was 0.76%.

The historical rank and industry rank for GoodRx Holdings's ROE % or its related term are showing as below:

GDRX' s ROE % Range Over the Past 10 Years
Min: -3.99   Med: -1.12   Max: 4.54
Current: 3.28

During the past 8 years, GoodRx Holdings's highest ROE % was 4.54%. The lowest was -3.99%. And the median was -1.12%.

GDRX's ROE % is ranked worse than
57.8% of 628 companies
in the Healthcare Providers & Services industry
Industry Median: 5.72 vs GDRX: 3.28

GoodRx Holdings  (NAS:GDRX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=4.676/619.124
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(4.676 / 776.024)*(776.024 / 1712.6545)*(1712.6545 / 619.124)
=Net Margin %*Asset Turnover*Equity Multiplier
=0.6 %*0.4531*2.7663
=ROA %*Equity Multiplier
=0.27 %*2.7663
=0.76 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=4.676/619.124
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (4.676 / 22.556) * (22.556 / 56.036) * (56.036 / 776.024) * (776.024 / 1712.6545) * (1712.6545 / 619.124)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.2073 * 0.4025 * 7.22 % * 0.4531 * 2.7663
=0.76 %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


GoodRx Holdings ROE % Related Terms


GoodRx Holdings ROE % Historical Data

* Premium members only.

The historical data trend for GoodRx Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GoodRx Holdings ROE % Chart

GoodRx Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial -3.27 -3.99 -1.12 2.21 4.54

GoodRx Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.41 7.92 0.72 3.57 0.76

GDRX vs OMDA, CERT, TALK: ROE % Comparison

For the Health Information Services subindustry, GoodRx Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GoodRx Holdings ROE % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, GoodRx Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where GoodRx Holdings's ROE % falls into.


GDRX
60GF Score
GoodRx Holdings Inc GDRX
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GoodRx Holdings ROE % Calculation

GoodRx Holdings's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=30.439/( (724.658+616.262)/ 2 )
=30.439/670.46
=4.54 %

GoodRx Holdings's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=4.676/( (616.262+621.986)/ 2 )
=4.676/619.124
=0.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.76% mean?
GoodRx Holdings (GDRX) has a ROE % of 0.76% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on GoodRx Holdings and its competitors. According to the industry distribution chart, GoodRx Holdings ranks #363 out of 628 companies in the Healthcare Providers & Services industry, placing it in the top 57.8%.
Is GoodRx Holdings' ROE % too high?
GoodRx Holdings' current ROE % is 0.76%. The Healthcare Providers & Services industry median ROE % is 5.72. GoodRx Holdings' value of 0.76% is 86.7% below this industry median. Based on the distribution chart, GoodRx Holdings ranks #363 out of 628 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, GoodRx Holdings has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does GoodRx Holdings' ROE % compare to OMDA and CERT?
According to the Healthcare Providers & Services industry distribution chart, GoodRx Holdings ranks #363 out of 628 companies for ROE %. This places GoodRx Holdings in the lower half of its industry. The industry median ROE % is 5.72. GoodRx Holdings' value of 0.76% is 86.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.72, based on 628 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GoodRx Holdings's current ROE % of 0.76% is 86.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on GoodRx Holdings and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GoodRx Holdings's current ROE % is 0.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GoodRx Holdings stock overvalued right now?
Based on GuruFocus' analysis, GoodRx Holdings (GDRX) is currently considered Possible Value Trap. The stock's GF Value™ is $5.66, compared to a current price of $2.70 — trading 52.3% below its estimated fair value. The current ROE % is 0.76% and 86.7% below the Healthcare Providers & Services industry median of 5.72. GoodRx Holdings' overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For GoodRx Holdings (GDRX), the current ROE % is 0.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GoodRx Holdings (GDRX) Overvalued in 2026?

Based on GuruFocus' analysis, GoodRx Holdings stock appears to be undervalued. The current stock price of $2.70 is trading 52.3% below its estimated GF Value™ of $5.66. GuruFocus considers GoodRx Holdings to be Possible Value Trap.

Key valuation signals for GDRX:

  • ROE %: 0.76%
  • GF Value™: $5.66 vs. price of $2.70 (52.3% below fair value)
  • GF Score™: 60/100 with 3 warning signs
  • Industry Position: 86.7% below the Healthcare Providers & Services median (#363 of 628)

No single metric tells the full story. See the GDRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


GoodRx Holdings Business Description

Other Exchanges 8GH:Germany
Address 2701 Olympic Boulevard, Santa Monica, CA, USA, 90404
GoodRx Holdings Inc is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and provides access to negotiated prices through codes that can be used to save money on prescriptions across the United States. GoodRx generates revenue from core business from pharmacy benefit managers (PBMs) that manage formularies and prescription transactions including establishing pricing between consumers and pharmacies. It also offers various healthcare products and services, including pharma manufacturer solutions, subscriptions, and telehealth services.
60GF Score

Get the complete analysis for GDRX

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.70
Price
$5.66
GF Value